CV Lattes
Universidade Estadual de Campinas (UNICAMP). Faculdade de Ciências Farmacêuticas (FCF) (Institutional affiliation from the last research proposal) Birthplace: Brazil
graduation at Farmácia from Pontifícia Universidade Católica de Campinas (2013), master's at Clinical Medicine from Universidade Estadual de Campinas (2016) and doctorate at Department of Bioengineering and Therapeutic Sciences from University of California San Francisco (2019). Has experience in Pharmacy, focusing on Clinical pharmacy, pharmaceutical care and attention (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Ovarian cancer is the fifth death cause regarding malignant neoplasms in women. Thereby, in recent years, efforts have been made to demonstrate that inherited genetic markers in women with ovarian carcinoma, such as polymorphisms, may predict the response, resistance and toxicity to chemotherapy with platinum derivatives and paclitaxel, and survival. Furthermore, in ovarian carcinoma, sur…
Clinical pharmacy is the health science whose responsibility is to ensure and contribute with pharmaceutical knowledge that the use of medications must be safe and appropriate to improve patient care. In an oncology admission unit, patients receive multiple concomitant medications to treat their cancer, comorbidities and signs and symptoms related to cancer. The objective of this study wi…
In the pregnancy-puerperal cycle, women may develop complications requiring admission to the Intensive Care Unit (ICU). In this context, it is necessary to give special attention to pharmacotherapy used by the patient, evaluating the risks / benefits of drugs for the pregnant woman and the fetus, because the placenta is a permeable barrier and the effects can be lethal or teratogenic. In …
Paclitaxel is an antineoplastic drug frequently effective in first line treatment for ovarian, breast, lung and prostate cancer. However, cumulative dose of this agent is a significant predictor of sensory peripheral neuropathy. The first genome wide association studies on paclitaxel induced peripheral neuropathy (PIPN) identified a genetic variant in the ephrin receptor gene EPHA5 associ…
| 3 / 3 | Completed scholarships in Brazil |
| 1 / 1 | Completed scholarships abroad |
| 4 / 4 | All Scholarships |
| Associated processes | |